AU2019224051A1 - Compositions and methods for cellular immunotherapy - Google Patents

Compositions and methods for cellular immunotherapy Download PDF

Info

Publication number
AU2019224051A1
AU2019224051A1 AU2019224051A AU2019224051A AU2019224051A1 AU 2019224051 A1 AU2019224051 A1 AU 2019224051A1 AU 2019224051 A AU2019224051 A AU 2019224051A AU 2019224051 A AU2019224051 A AU 2019224051A AU 2019224051 A1 AU2019224051 A1 AU 2019224051A1
Authority
AU
Australia
Prior art keywords
cell
fusion protein
cells
domain
car
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2019224051A
Other languages
English (en)
Inventor
Stanley RIDDELL
Alexander SALTER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fred Hutchinson Cancer Center
Original Assignee
Fred Hutchinson Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fred Hutchinson Cancer Center filed Critical Fred Hutchinson Cancer Center
Publication of AU2019224051A1 publication Critical patent/AU2019224051A1/en
Assigned to FRED HUTCHINSON CANCER CENTER reassignment FRED HUTCHINSON CANCER CENTER Request for Assignment Assignors: FRED HUTCHINSON CANCER RESEARCH CENTER
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/22—Intracellular domain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2019224051A 2018-02-26 2019-02-21 Compositions and methods for cellular immunotherapy Abandoned AU2019224051A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862635450P 2018-02-26 2018-02-26
US62/635,450 2018-02-26
US201862676787P 2018-05-25 2018-05-25
US62/676,787 2018-05-25
US201862739792P 2018-10-01 2018-10-01
US62/739,792 2018-10-01
PCT/US2019/019014 WO2019165116A1 (en) 2018-02-26 2019-02-21 Compositions and methods for cellular immunotherapy

Publications (1)

Publication Number Publication Date
AU2019224051A1 true AU2019224051A1 (en) 2020-09-03

Family

ID=65818064

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019224051A Abandoned AU2019224051A1 (en) 2018-02-26 2019-02-21 Compositions and methods for cellular immunotherapy

Country Status (7)

Country Link
US (1) US20210079061A1 (cg-RX-API-DMAC7.html)
EP (1) EP3759130A1 (cg-RX-API-DMAC7.html)
JP (1) JP2021514631A (cg-RX-API-DMAC7.html)
CN (1) CN112041335A (cg-RX-API-DMAC7.html)
AU (1) AU2019224051A1 (cg-RX-API-DMAC7.html)
CA (1) CA3091138A1 (cg-RX-API-DMAC7.html)
WO (1) WO2019165116A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7291396B2 (ja) 2016-11-22 2023-06-15 ティーシーアール２ セラピューティクス インク． 融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法
US12077598B2 (en) * 2018-03-16 2024-09-03 H. Lee Moffitt Cancer Center And Research Institute, Inc. Chimeric antigen receptors with mutated CD28 phosphorylation sites
GB201900858D0 (en) * 2019-01-22 2019-03-13 Price Nicola Kaye Receptors providing targeted costimulation for adoptive cell therapy
TW202110873A (zh) 2019-04-30 2021-03-16 美商聖堤生物科技股份有限公司 嵌合受體及其使用方法
JP7439279B2 (ja) * 2020-02-13 2024-02-27 イミュノファーム テクノロジー カンパニー リミテッド キメラ抗原受容体の最適化
US20230227821A1 (en) * 2020-04-07 2023-07-20 University Health Network Compositions and methods for enhancing activation and cytolytic activity of cd8+ t cells through disruption of the saga (spt-ada-gcn5-acetyltransferase) complex
CA3188143A1 (en) * 2020-06-25 2021-12-30 The Methodist Hospital Antigen-specific t cell receptors and chimeric antigen receptors, and methods of use in immune signaling modulation for cancer immunotherapy
AU2021312871A1 (en) * 2020-07-21 2023-02-09 Allogene Therapeutics, Inc. Chimeric antigen receptors with enhanced signaling and activities and uses thereof
CA3215085A1 (en) * 2021-04-08 2022-10-13 Immvira Biopharmaceuticals Co., Limited Genetically modified oncolytic herpes simplex virus delivering chemokine and tumor associated/specific antigen
CN116102658B (zh) * 2021-11-09 2025-04-29 四川大学华西医院 基于gas6构建的嵌合抗原受体免疫细胞制备及其应用
US20250319130A1 (en) * 2022-06-01 2025-10-16 Seattle Children’s Hospital d/b/a Seattle Children’s Research Institute Recombinant receptors binding b cell activation factor receptor and uses thereof
CN117065029A (zh) * 2022-10-31 2023-11-17 徐州医科大学 C1qbp在提高t细胞抗肿瘤能力中的应用
CN118206620A (zh) * 2022-12-09 2024-06-18 上海细胞治疗集团股份有限公司 一种多肽标签及其应用
CN119710010A (zh) * 2025-02-18 2025-03-28 广州医科大学附属第三医院（广州重症孕产妇救治中心、广州柔济医院） Slc7a5在作为宫颈癌的不良预后标志物和/或制备防治宫颈癌药物中的应用

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US5420032A (en) 1991-12-23 1995-05-30 Universitge Laval Homing endonuclease which originates from chlamydomonas eugametos and recognizes and cleaves a 15, 17 or 19 degenerate double stranded nucleotide sequence
US5792632A (en) 1992-05-05 1998-08-11 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
US5525503A (en) * 1993-09-28 1996-06-11 Dana-Farber Cancer Institute, Inc. Signal transduction via CD28
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
GB9518220D0 (en) 1995-09-06 1995-11-08 Medical Res Council Checkpoint gene
US6410319B1 (en) 1998-10-20 2002-06-25 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
DE10113776B4 (de) 2001-03-21 2012-08-09 "Iba Gmbh" Isoliertes streptavidinbindendes, kompetitiv eluierbares Peptid, dieses umfassendes Fusionspeptid, dafür codierende Nukleinsäure, Expressionsvektor, Verfahren zur Herstellung eines rekombinanten Fusionsproteins und Verfahren zum Nachweis und/oder zur Gewinnung des Fusionsproteins
AU2003215869B2 (en) 2002-03-15 2008-04-24 Cellectis Hybrid and single chain meganucleases and use thereof
EP3202899B1 (en) 2003-01-28 2020-10-21 Cellectis Custom-made meganuclease and use thereof
JP2008527001A (ja) 2005-01-13 2008-07-24 ザ ジョンズ ホプキンス ユニバーシティー 前立腺幹細胞抗原ワクチンおよびその使用
US20070036773A1 (en) 2005-08-09 2007-02-15 City Of Hope Generation and application of universal T cells for B-ALL
ES2582091T3 (es) 2005-10-18 2016-09-09 Precision Biosciences Meganucleasas diseñadas racionalmente con especificidad de secuencia y afinidad de unión a ADN alteradas
WO2007051077A2 (en) 2005-10-28 2007-05-03 The Regents Of The University Of California Methods and compounds for lymphoma cell detection and isolation
US8119772B2 (en) 2006-09-29 2012-02-21 California Institute Of Technology MART-1 T cell receptors
US20110245167A1 (en) 2008-12-12 2011-10-06 The University Of Toledo NaK-ATPase-Derived Peptide SRC Inhibitors and Ouabain Antagonists and Uses Thereof
EP2210903A1 (en) 2009-01-21 2010-07-28 Monoclonal Antibodies Therapeutics Anti-CD160 monoclonal antibodies and uses thereof
CA2759733C (en) 2009-04-23 2019-09-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-human ror1 antibodies
EP2258719A1 (en) 2009-05-19 2010-12-08 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Multiple target T cell receptor
US8586526B2 (en) 2010-05-17 2013-11-19 Sangamo Biosciences, Inc. DNA-binding proteins and uses thereof
WO2011059836A2 (en) 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
US9150647B2 (en) 2009-12-18 2015-10-06 Kancera Ab Biological inhibitors of ROR1 capable of inducing cell death
US9242014B2 (en) 2010-06-15 2016-01-26 The Regents Of The University Of California Receptor tyrosine kinase-like orphan receptor 1 (ROR1) single chain Fv antibody fragment conjugates and methods of use thereof
EP3828205A1 (en) 2010-10-01 2021-06-02 Oxford BioTherapeutics Ltd Anti-ror1 antibodies
ES2657970T3 (es) 2010-12-01 2018-03-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anticuerpos contra ROR1 de conejo/ser humano quiméricos
US9233125B2 (en) 2010-12-14 2016-01-12 University Of Maryland, Baltimore Universal anti-tag chimeric antigen receptor-expressing T cells and methods of treating cancer
EP3604339B1 (en) 2011-01-14 2021-03-10 The Regents Of The University Of California Therapeutic antibodies against ror-1 protein and methods for use of same
US20130071414A1 (en) 2011-04-27 2013-03-21 Gianpietro Dotti Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies
US9676854B2 (en) 2011-08-15 2017-06-13 Medimmune, Llc Anti-B7-H4 antibodies and their uses
WO2013044225A1 (en) 2011-09-22 2013-03-28 The Trustees Of The University Of Pennsylvania A universal immune receptor expressed by t cells for the targeting of diverse and multiple antigens
AU2013266968B2 (en) 2012-05-25 2017-06-29 Emmanuelle CHARPENTIER Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
BR122020002986A8 (pt) 2012-08-20 2023-04-18 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Método e composições para imunoterapia celular
ES2702315T3 (es) 2012-08-24 2019-02-28 Univ California Anticuerpos y vacunas para su uso en tratar cánceres ROR1 e inhibir metástasis
US20140186843A1 (en) 2012-12-12 2014-07-03 Massachusetts Institute Of Technology Methods, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
CA2894879A1 (en) 2012-12-19 2014-06-26 Amplimmune, Inc. B7-h4 specific antibodies, and compositions and methods of use thereof
CA2930877A1 (en) 2013-11-18 2015-05-21 Crispr Therapeutics Ag Crispr-cas system materials and methods
NZ759969A (en) 2013-12-20 2022-12-23 Fred Hutchinson Cancer Center Tagged chimeric effector molecules and receptors thereof
CN113307880B (zh) * 2014-01-13 2025-07-04 希望之城公司 在Fc间隔物区中具有突变的嵌合抗原受体(CAR)及其使用方法
EP2990416B1 (en) 2014-08-29 2018-06-20 GEMoaB Monoclonals GmbH Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
WO2016040724A1 (en) 2014-09-12 2016-03-17 Genentech, Inc. Anti-b7-h4 antibodies and immunoconjugates
RU2017115315A (ru) 2014-10-03 2018-11-08 Дана-Фарбер Кэнсер Инститьют, Инк. Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения
WO2016094873A2 (en) 2014-12-12 2016-06-16 Emergent Product Development Seattle, Llc Receptor tyrosine kinase-like orphan receptor 1 binding proteins and related compositions and methods
WO2016168769A1 (en) 2015-04-15 2016-10-20 The California Institute For Biomedical Research Chimeric receptor t cell switches for her2
US11091546B2 (en) 2015-04-15 2021-08-17 The Scripps Research Institute Optimized PNE-based chimeric receptor T cell switches and uses thereof
SG11201803098VA (en) 2015-10-30 2018-05-30 Nbe Therapeutics Ag Anti-ror1 antibodies
ES2912408T3 (es) * 2017-01-26 2022-05-25 Novartis Ag Composiciones de CD28 y métodos para terapia con receptores quiméricos para antígenos
KR20200027508A (ko) * 2017-07-07 2020-03-12 에이치 리 모피트 캔서 센터 앤드 리서어치 인스티튜트 아이엔씨 돌연변이된 cd28 공동자극 도메인을 갖는 키메라 항원 수용체
JP2021500859A (ja) * 2017-09-22 2021-01-14 エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド Ｎｆｋｂシグナル伝達の増強を伴うキメラ抗原受容体

Also Published As

Publication number Publication date
EP3759130A1 (en) 2021-01-06
US20210079061A1 (en) 2021-03-18
JP2021514631A (ja) 2021-06-17
CN112041335A (zh) 2020-12-04
WO2019165116A1 (en) 2019-08-29
CA3091138A1 (en) 2019-08-29

Similar Documents

Publication Publication Date Title
AU2019224051A1 (en) Compositions and methods for cellular immunotherapy
JP7037577B2 (ja) 高親和性ｍａｇｅ－ａ１特異的ｔｃｒ及びその使用
US10709775B2 (en) Cells for immunotherapy engineered for targeting CD38 antigen and for CD38 gene inactivation
US20210246423A1 (en) Methods for improving the efficacy and expansion of immune cells
EP4537839B1 (en) Method and compositions for cellular immunotherapy
US20240165232A1 (en) Chimeric receptor proteins and uses thereof
US20210069241A1 (en) Compositions and methods of immunotherapy targeting tigit and/or cd112r or comprising cd226 overexpression
EP3558348A1 (en) Engineered t cells for the treatment of cancer
KR20170128234A (ko) Ror1에 특이적인 항체 및 키메라 항원 수용체
KR20170032406A (ko) 입양 세포 치료를 위한 조작된 세포
CN110267973A (zh) 表达嵌合抗原受体的t细胞
US20250018036A1 (en) Immunotherapy targeting sox2 antigens
KR20200041377A (ko) Strep-tag 특이적 결합 단백질 및 그 용도
WO2022056304A1 (en) Compositions and methods for tcr reprogramming using nectin-4 specific fusion proteins
JP7737978B2 (ja) Ｗｔ－１に特異的なｔ細胞免疫療法
US20220401537A1 (en) Chimeric receptor proteins and uses thereof
HK40097595A (zh) 靶向sox2抗原的免疫治疗
WO2023133424A2 (en) Compositions and methods for tcr reprogramming using fusion proteins and anti-pd-1 fusion peptides
WO2023172967A2 (en) Compositions and methods for tcr reprogramming using gpc3 specific fusion proteins
HK40102796A (zh) 用於癌症治疗的诱导细胞损伤的治疗药物
HK40073285A (en) T-cell immunotherapy specific for wt-1

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: FRED HUTCHINSON CANCER CENTER

Free format text: FORMER APPLICANT(S): FRED HUTCHINSON CANCER RESEARCH CENTER

MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application